Gufic Biosciences Limited — Investor Meet, 21-08-2026: Analysts/Institutional Investor Meet/Con. Call Updates

Gufic Biosciences delivered strong Q1 FY27 results, with revenue at INR 260.8 Cr and PAT at INR 22.46 Cr, boosting EBITDA margin to 18.09%. The Indore plant is on track, with new depot and microsphere suites nearing completion and EU certification anticipated within 1-2 months. The company is strategically expanding product lines, including GLP-1 CMO operations with Hetero and new aesthetic fillers. International markets are shifting towards IP-led growth. Management maintains a 15-20% YOY growth target, focusing on optimizing product mix for higher revenue from existing capacity. Operating leverage from Indore is expected by mid-FY28.